Compare Avalanche Treasury Corporation Class A Common Stock (AVAT) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avalanche Treasury Corporation Class A Common Stock vs Crispr Therapeutics AG — how do they compare? Avalanche Treasury Corporation Class A Common Stock trades at $0.34 (market cap $15.33M), while Crispr Therapeutics AG trades at $54 (market cap $5.23B). The key difference: Crispr Therapeutics AG is far larger — about 341.2× Avalanche Treasury Corporation Class A Common Stock's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Avalanche Treasury Corporation Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| AVAT | CRSP | |
|---|---|---|
Market Cap | $15.33M | $5.23B |
Sector | Financials | Health |
52-Week High | $10.75 | $76.78 |
52-Week Low | $0.30 | $44.34 |
Enterprise Value | $15.33M | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVAT trades at $0.3426, up 1.75% today, with a bearish technical signal from moving averages and a P/E of 12. The company reported net income of $8.28 million for 2025, but negative operating cash flow of $930,710 raises concerns about liquidity. Recent news highlights its Nasdaq listing as Avalanche Treasury Co., focusing on capital allocation within its ecosystem.
The outlook is mixed: profitability and low valuation offer potential upside, but cash flow challenges and bearish technicals present risks. Investor sentiment is cautious due to operational losses, though the public listing may attract institutional interest.
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
